If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated ...

“It came as a surprise that our approach works so well,” Lu said. In preclinical (non-human) studies, the vaccine completely ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit writes about the key takeaways from the ASCO 2025 Annual ...

Two recent studies from Dr. Sita Kugel’s lab at Fred Hutch Cancer Center identify a key biological signature that not only ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% ...

Portions of the resected primary pancreatic tumor were fixed in 10 per cent neutral formalin, Bouin's fluid, Zenker's formol, 2 per cent gluteraldehyde in cacodylate buffer at pH 7.2 and 1 per ...

Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company partners with patient advocacy groups to identify unmet needs and prioritize patient-centered benefits in the ...

Alibaba Group has unveiled what it claims is the world’s first artificial intelligence model capable of detecting gastric ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

The weight-loss injection boom that swept through Hollywood and boardrooms alike is now facing a potentially deadly reckoning ...

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somato ...